Study of Erlotinib in Combination With Bortezomib

NCT00895687 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: Erlotinib Hydrochloride
DRUG: Bortezomib

Sponsor

M.D. Anderson Cancer Center